FENC 4.54 Fennec Pharmaceuticals Inc.
| Range: | 4.09-11.92 | Vol Avg: | 84401 | Last Div: | 0 | Changes: | -0.11 |
| Beta: | 0.25 | Cap: | 0.12B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Sep 15 2017 | Empoloyees: | 29 | ||
| CUSIP: | 31447P100 | CIK: | 0001211583 | ISIN: | CA31447P1009 | Country: | US |
| CEO: | Mr. Rostislav Raykov | Website: | https://www.fennecpharma.com | ||||
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Stock Details
FENC 17
Fennec price target lowered to $17 from $20 at Craig-Hallum
Chase Knickerbocker·Wed May 15 2024
Craig-Hallum
FENC 15
Fennec Pharmaceuticals Inc. (FENC) PT Lowered to $15 at H.C. Wainwright
Raghuram Selvaraju·Wed May 15 2024
H.C. Wainwright
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow